Haemonetics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 22 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.4 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 107.97% -2.44pp
- Institutions
- 420 +22
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 28 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| Christopher Simon | Chief Executive Officer | 0.76% |
| Michelle Basil | General Counsel | 0.08% |
| Robert Abernathy | Independent Director | 0.05% |
| Mark Kroll | Independent Director | 0.05% |
| Laurie Miller | Chief Human Resources Officer | 0.05% |
| Charles Dockendorff | Former Independent Director | 0.05% |
| Ellen Zane | Independent Chairperson | 0.04% |
| James D'Arecca | CFO, Executive VP & Financial Officer | 0.04% |
| Claire Pomeroy | Independent Director | 0.04% |
| Michael Coyle | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-10 | Farris Maryanne Maunsell | VP, Chief Accounting Officer & Principal Accounting Officer | Open Market Disposition | -414 | $120.99 |
| 2026-11-10 | Farris Maryanne Maunsell | VP, Chief Accounting Officer & Principal Accounting Officer | Derivative Exercise and Sale | -2,146 | $70.31–121.10 |
| 2026-10-29 | Roy Galvin | Executive Vice President | Sale to Issuer | -146 | $119.65 |
| 2026-07-23 | Robert Abernathy | Independent Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Michael Coyle | Independent Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Ellen Zane | Independent Chairperson | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Claire Pomeroy | Independent Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Mark Kroll | Independent Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Martin Madaus | Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Diane Bryant | Independent Director | Other Acquisition | +2,538 | -- |
| 2026-07-23 | Lloyd Johnson | Independent Director | Other Acquisition | +2,538 | -- |
| 2026-06-04 | Laurie Miller | Chief Human Resources Officer | Sale to Issuer | -313 | $71.28 |
| 2026-06-04 | Farris Maryanne Maunsell | VP, Chief Accounting Officer & Principal Accounting Officer | Sale to Issuer | -259 | $71.28 |
| 2026-05-14 | Michelle Basil | General Counsel | Sale to Issuer | -2,913 | $56.29 |
| 2026-05-14 | Michelle Basil | General Counsel | Other Acquisition | +28,424 | -- |
| 2026-05-14 | Christopher Simon | Chief Executive Officer | Sale to Issuer | -9,681 | $56.29 |
| 2026-05-14 | Christopher Simon | Chief Executive Officer | Other Acquisition | +78,344 | -- |
| 2026-05-14 | James D'Arecca | CFO, Executive VP & Financial Officer | Sale to Issuer | -2,505 | $56.29 |
| 2026-05-14 | James D'Arecca | CFO, Executive VP & Financial Officer | Other Acquisition | +29,312 | -- |
| 2026-05-14 | Laurie Miller | Chief Human Resources Officer | Sale to Issuer | -948 | $56.29 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Haemonetics discussion 0 comments